JOHN KIRKWOOD to Mice
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Mice.
Connection Strength
0.261
-
Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
Score: 0.053
-
LAG-3 and PD-1 synergize on CD8+ T?cells to drive T cell exhaustion and hinder autocrine IFN-?-dependent anti-tumor immunity. Cell. 2024 Aug 08; 187(16):4355-4372.e22.
Score: 0.018
-
GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024 May 17; 15:328-344.
Score: 0.018
-
Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002 Apr; 13(2):119-34.
Score: 0.015
-
Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. SLAS Discov. 2021 06; 26(5):712-729.
Score: 0.014
-
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020 10 15; 26(20):5520-5533.
Score: 0.013
-
Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 2000 Jun 15; 88(12):2693-702.
Score: 0.013
-
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019 03 07; 4(5).
Score: 0.012
-
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell. 2019 01 14; 35(1):33-45.e6.
Score: 0.012
-
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight. 2017 09 21; 2(18).
Score: 0.011
-
Interferon-? Drives Treg Fragility to Promote Anti-tumor Immunity. Cell. 2017 Jun 01; 169(6):1130-1141.e11.
Score: 0.011
-
Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Rep. 2016 Apr 05; 15(1):171-180.
Score: 0.010
-
PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41.
Score: 0.009
-
Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice. J Virol Methods. 2013 Jan; 187(1):6-14.
Score: 0.008
-
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
Score: 0.008
-
Interferon alpha in combination with other biologics: the scientific rationale. Br J Haematol. 1991 Oct; 79 Suppl 1:78-80.
Score: 0.007
-
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32.
Score: 0.007
-
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15; 177(4):2717-27.
Score: 0.005
-
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004 Mar; 50(3):564-73.
Score: 0.004
-
In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome. Cancer Res. 1983 Jul; 43(7):3434-40.
Score: 0.004
-
Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res. 2001 Mar; 7(3 Suppl):974s-979s.
Score: 0.004
-
Cytokine-based therapy for melanoma: pre-clinical studies. Forum (Genova). 2000 Jul-Sep; 10(3):204-26.
Score: 0.003
-
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1993 Apr; 13(3):201-7.
Score: 0.002